Email
Password
Remember meForgot password?
    Log in with Twitter
Press Release

Global Biosimilar Drug Sales Market Revenue Status and Forecast to 2022

QYResearch is a leading market research publisher which pursuits high product quality with the belief that quality is the soul of business and consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience.

This press release was orginally distributed by SBWire

City of Industry, CA -- (SBWIRE) -- 06/14/2018 -- This report studies the global Biosimilar Drug market status and forecast, categorizes the global Biosimilar Drug market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).

Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.

Ask for Discount on Research Report@ https://www.qyresearch.com/request-discount/form/21477/global-biosimilar-drug-sales-market

As healthcare costs continue to rise, biosimilars offer new therapeutic options with the potential for cost savings to the healthcare system. With anticipated savings, biosimilars bring hope that there will be expanded access for patients to not only these known therapies, but also to new innovative medicines. At Amgen, serving patients is at the core of what we do and it is why we're using our more than 35 years of biologics experience to develop high-quality biosimilars.

First, in pharmerging markets, both governments and patients struggle to pay for biosimilars, which encouraged the demand of biosimilars, therefore in the future the biosimilars will grow around 20%.

Second, generally, biosimilars industry is still in their infancy in China. It is commonly believed that the next 10 to 15 years is the golden period of the development of biosimilars.

Third, for the biosimilars industry, technical barriers will be much smaller, in the next few years, there will be more and more enterprises going into biosimilars industry.

Request Sample Copy of Report@ https://www.qyresearch.com/sample-form/form/21477/global-biosimilar-drug-sales-market

Forth, most of biosimilars manufacturer are concentrated in US, Germany, UK and other developed countries.

At last, through the research we tend to believe that the biosimilars, now is a chance for newcomers and they will greatly change the industry.

The global Biosimilar Drug market is valued at xx million US$ in 2017 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2018-2025.

About QY Research
QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert's resources (included energy automotive chemical medical ICT consumer goods etc.

For more information on this press release visit: http://www.sbwire.com/press-releases/global-biosimilar-drug-sales-market-revenue-status-and-forecast-to-2022-994366.htm

Media Relations Contact

Rahul Singh
Director - Digital Marketing
QY Research, Inc
Telephone: 1-626-295-2442
Email: Click to Email Rahul Singh
Web: https://www.qyresearch.com/index/detail/21477/global-biosimilar-drug-sales-market

Latest News
Top News